(Q35013215)

5 August 2017

1 reference

title

Molecular mechanisms of novel therapeutic approaches for multiple myeloma (English)

1 reference

5 August 2017

Teru Hideshima

1

1 reference

PubMed ID

12459731

5 August 2017

Kenneth C Anderson

series ordinal

2

1 reference

PubMed ID

12459731

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

5 August 2017

Nature Reviews Cancer

1 reference

5 August 2017

2

1 reference

5 August 2017

927-937

1 reference

5 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc952

5 August 2017

0 references

cites work

Multiple myeloma: evolving genetic events and host interactions

1 reference

Targeted therapy for multiple myeloma

31 March 2020

1 reference

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

31 March 2020

1 reference

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

31 March 2020

1 reference

Randomized trial experience of the Intergroupe Francophone du Myélome

31 March 2020

1 reference

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

31 March 2020

1 reference

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

31 March 2020

1 reference

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

31 March 2020

1 reference

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

31 March 2020

1 reference

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

31 March 2020

1 reference

Current therapy for multiple myeloma

31 March 2020

1 reference

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

31 March 2020

1 reference

Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells

31 March 2020

1 reference

Clinical translation of angiogenesis inhibitors

31 March 2020

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

31 March 2020

1 reference

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

31 March 2020

1 reference

Thalidomide is an inhibitor of angiogenesis

31 March 2020

1 reference

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

31 March 2020

1 reference

Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma

31 March 2020

1 reference

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

31 March 2020

1 reference

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

31 March 2020

1 reference

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants

31 March 2020

1 reference

Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma

31 March 2020

1 reference

Interleukin-6 inhibits apoptosis of malignant plasma cells

31 March 2020

1 reference

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

31 March 2020

1 reference

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

31 March 2020

1 reference

Interleukin-21 is a growth and survival factor for human myeloma cells

31 March 2020

1 reference

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

31 March 2020

1 reference

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

31 March 2020

1 reference

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

31 March 2020

1 reference

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

31 March 2020

1 reference

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

31 March 2020

1 reference

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

31 March 2020

1 reference

Modulation of multidrug resistance (MDR) in hematological malignancies

31 March 2020

1 reference

Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma

31 March 2020

1 reference

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

31 March 2020

1 reference

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

31 March 2020

1 reference

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

31 March 2020

1 reference

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

31 March 2020

1 reference

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

31 March 2020

1 reference

Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells

31 March 2020

1 reference

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

31 March 2020

1 reference

The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway.

31 March 2020

1 reference

Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils

31 March 2020

1 reference

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

31 March 2020

1 reference

NF-kappa B as a therapeutic target in multiple myeloma

31 March 2020

1 reference

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

31 March 2020

1 reference

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

31 March 2020

1 reference

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

31 March 2020

1 reference

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

31 March 2020

1 reference

Thalidomide: a novel template for anticancer drugs

31 March 2020

1 reference

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

31 March 2020

1 reference

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

31 March 2020

1 reference

How proteolysis drives the cell cycle

31 March 2020

1 reference

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

31 March 2020

1 reference

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

31 March 2020

1 reference

Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells

31 March 2020

1 reference

Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma

31 March 2020

1 reference

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

31 March 2020

1 reference

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

31 March 2020

1 reference

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

31 March 2020

1 reference

Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase

31 March 2020

1 reference

2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site

31 March 2020

1 reference

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

31 March 2020

1 reference

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

31 March 2020

1 reference

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

31 March 2020

1 reference

Current status of clinical trials of farnesyltransferase inhibitors.

31 March 2020

1 reference

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

31 March 2020

1 reference

Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells

31 March 2020

1 reference

Assessment of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma

31 March 2020

1 reference

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

31 March 2020

1 reference

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

31 March 2020

1 reference

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

31 March 2020

1 reference

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

31 March 2020

1 reference

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

31 March 2020

1 reference

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

31 March 2020

1 reference

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

31 March 2020

1 reference

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment

31 March 2020

1 reference

Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC952

1 reference

5 August 2017

1 reference

PubMed ID

12459731